Investors & Media

Corporate Profile

Corporate Profile

Corporate Profile

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders.  Sage’s lead product is approved by the U.S. Food and Drug Administration (FDA) for postpartum depression.  Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.

Investor Inquiries: ir@sagerx.com
Media Inquiries: media@sagerx.com

Copyright West LLC. Minimum 15 minutes delayed.